[ad_1]
The efficacy of the antiparasitic drug ivermectin in the treatment of patients with new coronaviruses is “promising”, the IECDDR, b. In an event on Monday (December 6), ICDDR, B reported that patients with mild COVID-19 infections admitted to hospital for COVID-19 who received a five-day course of ivermectin had a lower severity of the disease. infection. They have been negative Kovid-19 in the RTPCR test.
But ICDDR, says B, is the result of a small-scale study. Much more research is needed to determine if this drug will be used to treat coronavirus patients.
Professor of Medicine at Dhaka Medical College Hospital and member Secretary of the Treatment Protocol Committee for Covid-19 Prof. Dr. involved in the research work. Ahmedul Kabir said it was the result of a limited study. It will not be possible to reach a final decision with these results. This requires a large-scale investigation. It cannot be used to treat Covid-19 patients at this time. It can be added to the national guide for clinical trials.
Bir senior scientist ICDDR presented the keynote address at the seminar. Wasif Ahmed Khan. ICDDR, B conducted the study from June 16 to September 18 at Kurmitola General Hospital, Dhaka Medical College Hospital and Mugda General Hospital in the capital.
In the study, 22 out of 6 patients received 12 grams of oral ivermectin daily for five days, 23 patients received one dose of ivermectin with doxycycline (200 mg the first day and then 100 mg twice daily for 4 days), and 23 received placebo.
Based on the results of the study, ICDDR, B said that in 14 days, only 6% of those taking ivermectin were Covid-19 free, meaning they were shown to be Covid-19 free in the RTPCR test.
Eighty-one percent of the patients who received ivermectin and doxycycline and 30 percent of those who received a placebo became coronary.
According to the research report, on the third day of application, only 16 percent of patients who received ivermectin, 3 percent of patients who received ivermectin and doxycycline, and 3 percent of patients who received placebo were left virus free. On the seventh day the fruit was 50 percent, 30 percent and 13 percent.
According to the International Journal of Infectious Diseases, IJID, published December 2, ICDDR, b. The Managing Director of Bezimco Pharmaceuticals Limited, Nazmul Hasan MP, was present as a keynote guest at the seminar.
“We are delighted to be able to assist in the ivermectin clinical trial,” he said. It is an attempt to find profitable solutions in the fight against the Kovid-19 epidemic. We are delighted with the potential results of this study and it will really strengthen our fight against Covid-19 and help prevent many premature deaths.
ICDDR, Acting Executive Director of BIR and Senior Director of the Department of Nutrition and Clinical Services. Tahmid Ahmed.
He said that in low- and middle-income countries like Bangladesh, finding an affordable and easily accessible medical system to deal with this epidemic is very important. We are seeking assistance in conducting a larger trial using only ivermectin to assist decision makers regarding Covid-19 treatment.
He thanked Beximco Pharmaceuticals Limited, the Department of Health, the Department of Drug Administration, the Bangladesh Medical Research Council, and the hospitals that participated in the study for their support in this study.
General Director of the Brigade of the General Hospital of Kurmitola. Jamil Ahmed, a doctor from Bangladesh. In attendance were Tariq Alam, Ayub Khan, Director of the Drug Administration Department, Rabbur Reza, Executive Director of Beximco Pharmaceuticals.
[ad_2]
